Study identifies new gene that can increase chemotherapeutic response in medulloblastomas

brain tumor
Credit: Unsplash/CC0 Public Domain

An international team led by the Department of Neurosurgery, Niigata University, has identified a new gene called Schlafen11 (SLFN11) whose expression is tightly correlated with the response to chemotherapy in medulloblastomas, a highly malignant brain tumor affecting pediatric, adolescent, and young adult populations.

The team led by Dr. Manabu Natsumeda, first noticed that SLFN11 is highly expressed in almost all cases of WNT-activated medulloblastomas, which is the molecular subgroup with the best prognosis.

Further studies using medulloblastoma cell lines showed that genetically manipulating SLFN11 led to drastic changes in response to , a key drug for treating this deadly tumor.

"Some cases of medulloblastomas respond better to treatment than others, but we did not why. We can now better anticipate which cases will respond to . We even found that by using a different drug called HDAC inhibitor, we can increase SLFN11 levels in tumors and make them more responsive to cisplatin," explains Dr. Natsumeda.

The results of the study were published online in the journal Neuro-Oncology on October 23, 2022.

More information: Epigenetic upregulation of Schlafen11 renders WNT- and SHH- activated medulloblastomas sensitive to cisplatin, Neuro-Oncology (2022). DOI: 10.1093/neuonc/noac243

Provided by Niigata University
Citation: Study identifies new gene that can increase chemotherapeutic response in medulloblastomas (2022, November 8) retrieved 1 March 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children


Feedback to editors